Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Edwards Sells LifeStent Peripheral Business To Bard For $140 Million

This article was originally published in The Gray Sheet

Executive Summary

Edwards Lifesciences is giving up on the peripheral vascular market to focus its resources on its heart valve and critical care businesses

You may also be interested in...



Edwards Looks To Smaller-Diameter Transcatheter Valve In 2010

Edwards Lifesciences hopes to overcome one of its biggest competitive disadvantages in the European transcatheter valve market early next year with the planned launch of a smaller-profile product

Edwards Looks To Smaller-Diameter Transcatheter Valve In 2010

Edwards Lifesciences hopes to overcome one of its biggest competitive disadvantages in the European transcatheter valve market early next year with the planned launch of a smaller-profile product

More questions for LifeStent

Edwards Lifesciences continues to expect FDA approval of LifeStent for use in the superficial femoral artery by the end of 2008, despite its announcement May 30 that FDA has more questions about preclinical bench testing for the device. FDA sought information on the device's bench testing last fall as well. The company completed the sale of the LifeStent product line in January to C.R. Bard, which now markets the stent in the U.S. for biliary applications, but Edwards maintains responsibility for FDA approval of the femoral artery indication. After approval, Edwards will transition manufacturing responsibilities for LifeStent to Bard (1"The Gray Sheet" Dec. 10, 2007, p. 15)

Related Content

UsernamePublicRestriction

Register

MT025567

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel